Molecular genetic markers in acute myelogenous leukemia—the good, the bad, and the intermediate

Le résumé fourni par la source

The application of molecular genetic markers in the work-up of various diseases carries a great significance for current clinical and diagnostic practice. This routine only became possible after the finalization of the Human Genome Project with mapping of genes, essential for human pathology. Incorporating high-resolution genetic techniques and a widely available international database has also had a major contribution to the evolution of this process. Regarding acute myelogenous leukemia, in particular, the knowledge of the most common and weighty diagnostic, prognostic, and predictive molecular genetic markers is already included in the well-established recommendations. With this review, we aim to summarize and present information regarding the most common molecular variants currently as well as their significance for a personalized approach.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.